At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Rituximab +2 moredrug
Likely dose
Rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma
In Brief
A Phase 1 clinical trial evaluating Rituximab, Bendamustine, and 1 other intervention for Lymphoma, Non-Hodgkin and 5 related conditions. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
CountriesUnited States
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartMay 2017
Primary CompletionAug 2020
Study CompletionNov 2020
TodayJul 2026
First PostedOct 6, 2014
Enrollment StartMay 10, 2017
Primary CompletionAug 22, 2020
Study CompletionNov 18, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.7 years ago
Interventions
Rituximabdrug
375 mg/m2 I.V. on Day 1 of each cycle
Bendamustinedrug
90 mg/m2 I.V. on Day 1 and 2 of each cycle
Vincristine sulfate liposome injectiondrug
Dose per dose escalation protocol, I.V. on Day 2 of each cycle